Cargando…
Elafin drives poor outcome in high grade serous ovarian cancers and basal-like breast tumors
High grade serous ovarian carcinoma (HGSOC) and basal-like breast cancer (BLBC) share many features including TP53 mutations, genomic instability and poor prognosis. We recently reported that Elafin is overexpressed by HGSOC and is associated with poor overall survival. Here, we confirmed that Elafi...
Autores principales: | Labidi-Galy, S. Intidhar, Clauss, Adam, Ng, Vivian, Duraisamy, Sekhar, Elias, Kevin M., Piao, Hui-Ying, Bilal, Erhan, Davidowitz, Rachel A., Lu, Yiling, Badalian-Very, Gayane, Györffy, Balázs, Kang, Un-Beom, Ficarro, Scott B., Ganesan, Shridar, Mills, Gordon B., Marto, Jarrod A., Drapkin, Ronny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112176/ https://www.ncbi.nlm.nih.gov/pubmed/24469047 http://dx.doi.org/10.1038/onc.2013.562 |
Ejemplares similares
-
Elafin: a double agent in breast and ovarian cancer
por: Feng, Yi, et al.
Publicado: (2015) -
Personalized medicine in hematology — A landmark from bench to bed
por: Badalian-Very, Gayane
Publicado: (2014) -
Clinical applications of microRNAs
por: Hydbring, Per, et al.
Publicado: (2013) -
Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
por: Terzic, Julie, et al.
Publicado: (2020) -
Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis
por: Levanon, Keren, et al.
Publicado: (2009)